Literature DB >> 7588300

Inactivation of activin-dependent transcription by kinase-deficient activin receptors.

K Tsuchida1, J M Vaughan, E Wiater, D Gaddy-Kurten, W W Vale.   

Abstract

Activin, a member of the transforming growth factor-beta superfamily, binds to two classes of cell surface receptors. These receptors, designated type I and type II, are structurally related members of transmembrane serine kinase superfamily. Antibodies specific for either type I or type II activin receptor can coprecipitate complexes containing both affinity-labeled receptors from activin-responsive cells. Two type I receptors show cell-specific expression and associate with the ligand-binding, type II receptors. To investigate the roles of the cytoplasmic receptor domains in signaling through a heteromeric ligand receptor complex, we have made kinase-deficient activin receptors and correlated their losses in kinase activity with inhibitory effects on an activin-dependent transcriptional response in activin-responsive cell lines. Wild-type activin type II receptors phosphorylate activin type I receptors in transfected COS cells. In contrast, kinase-deficient activin type II receptors fail to phosphorylate type I receptors in transfected COS cells and act as dominant negative mutants to block activin-induced transcriptional activity in both Chinese hamster ovary and K562 (human erythroleukemia) cells. Kinase-deficient activin type IB receptors also block activin-induced transcriptional activity in both Chinese hamster ovary and K562 cells, whereas kinase-deficient activin type I receptors have no effect in either cell line. These results indicate that kinase activities of both type II and type I receptors are required for activin signaling, and that the two type I receptors, which are expressed in a tissue-specific manner, are functionally distinct.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588300     DOI: 10.1210/endo.136.12.7588300

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.

Authors:  J J Lebrun; W W Vale
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

2.  Cripto forms a complex with activin and type II activin receptors and can block activin signaling.

Authors:  Peter C Gray; Craig A Harrison; Wylie Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

3.  The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse.

Authors:  Z Gu; M Nomura; B B Simpson; H Lei; A Feijen; J van den Eijnden-van Raaij; P K Donahoe; E Li
Journal:  Genes Dev       Date:  1998-03-15       Impact factor: 11.361

4.  Bone morphogenetic protein receptors and activin receptors are highly expressed in ossified ligament tissues of patients with ossification of the posterior longitudinal ligament.

Authors:  K Yonemori; T Imamura; Y Ishidou; T Okano; S Matsunaga; H Yoshida; M Kato; T K Sampath; K Miyazono; P ten Dijke; T Sakou
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

5.  Activin controls skin morphogenesis and wound repair predominantly via stromal cells and in a concentration-dependent manner via keratinocytes.

Authors:  Casimir Bamberger; Agnes Schärer; Maria Antsiferova; Birte Tychsen; Sandra Pankow; Mischa Müller; Thomas Rülicke; Ralf Paus; Sabine Werner
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

6.  The rasGAP-binding protein, Dok-1, mediates activin signaling via serine/threonine kinase receptors.

Authors:  Norio Yamakawa; Kunihiro Tsuchida; Hiromu Sugino
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

Review 7.  TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.

Authors:  Mai Abdel Mouti; Siim Pauklin
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

8.  Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.

Authors:  Qun Wei; Haiyan Liu; Miao Liu; Chunyan Yang; Jie Yang; Zhonghui Liu; Ping Yang
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

9.  Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages.

Authors:  D Chen; X Ji; M A Harris; J Q Feng; G Karsenty; A J Celeste; V Rosen; G R Mundy; S E Harris
Journal:  J Cell Biol       Date:  1998-07-13       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.